Long‐term safety and efficacy of N8‐GP in previously treated adults and adolescents with hemophilia A: Final results from pathfinder2-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Long‐term safety and efficacy of N8‐GP in previously treated adults and adolescents with hemophilia A: Final results from pathfinder2

Published:2020-06-16 Issue: Volume: Page:
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Giangrande Paul¹,Abdul Karim Faraizah²,Nemes Laszlo³,You Chur Woo⁴,Landorph Andrea⁵,Geybels Milan S.⁵,Curry Nicola⁶

Affiliation:

1. Department of Clinical and Laboratory Sciences University of Oxford Oxford UK

2. National Blood Centre Kuala Lumpur Malaysia

3. National Hemophilia Center Hemostasis Department Medical Center Hungarian Defence Forces Budapest Hungary

4. Pediatric Department Eulji University Hospital Daejeon Republic of Korea

5. Novo Nordisk A/S Søborg Denmark

6. Oxford Haemophilia and Thrombosis Centre and Oxford National Institute for Health Research Biomedical Research Centre Churchill Hospital Oxford UK

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jth.14959

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The immunogenicity, safety, and efficacy of N8-GP in previously untreated patients with severe hemophilia A: pathfinder6 end-of-trial results;Journal of Thrombosis and Haemostasis;2023-11

2. Cases of less‐than‐expected FVIII activity in previously treated patients during post‐marketing surveillance of N8‐GP;Haemophilia;2023-09-20

3. Antidrug antibodies against the polyethylene glycol moiety inhibit the procoagulant activity of therapeutic polyethylene glycolated factor VIII;Journal of Thrombosis and Haemostasis;2023-06

4. The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A;Blood Advances;2023-02-21

5. Reduced FVIII recovery associated with anti-FVIII PEG antibodies after BNT162b2 SARS-CoV-2 vaccination;Blood Advances;2023-01-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3